These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 30694684)

  • 1. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
    Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
    Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
    Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
    J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood-Brain Barrier: A PET Study on Nonhuman Primates.
    Tournier N; Goutal S; Auvity S; Traxl A; Mairinger S; Wanek T; Helal OB; Buvat I; Soussan M; Caillé F; Langer O
    J Nucl Med; 2017 Jan; 58(1):117-122. PubMed ID: 27493269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
    Tournier N; Goutal S; Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Caillé F; Breuil L; Stanek J; Freeman AF; Novarino G; Truillet C; Wanek T; Langer O
    J Cereb Blood Flow Metab; 2021 Jul; 41(7):1634-1646. PubMed ID: 33081568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
    Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
    J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
    Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and
    Verheijen RB; Yaqub M; Sawicki E; van Tellingen O; Lammertsma AA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR; Hendrikse NH; Steeghs N
    J Nucl Med; 2018 Jun; 59(6):973-979. PubMed ID: 29175983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissimilar Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice.
    Biali ME; Auvity S; Cisternino S; Smirnova M; Hacker M; Zeitlinger M; Mairinger S; Tournier N; Bauer M; Langer O
    Mol Pharm; 2023 Nov; 20(11):5877-5887. PubMed ID: 37883694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
    Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
    J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [
    Hernández Lozano I; Bauer M; Wulkersdorfer B; Traxl A; Philippe C; Weber M; Häusler S; Stieger B; Jäger W; Mairinger S; Wanek T; Hacker M; Zeitlinger M; Langer O
    Mol Pharm; 2020 Jan; 17(1):316-326. PubMed ID: 31790256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-binding cassette transporter inhibitor potency and substrate drug affinity are critical determinants of successful drug delivery enhancement to the brain.
    Lentzas A; de Gooijer MC; Zuidema S; Meurs A; Çitirikkaya CH; Venekamp N; Beijnen JH; van Tellingen O
    Fluids Barriers CNS; 2024 Aug; 21(1):62. PubMed ID: 39103921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
    Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
    Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
    Tang SC; Lagas JS; Lankheet NA; Poller B; Hillebrand MJ; Rosing H; Beijnen JH; Schinkel AH
    Int J Cancer; 2012 Jan; 130(1):223-33. PubMed ID: 21351087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
    Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
    Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of the dual ABCB1 and ABCG2 inhibitor tariquidar on the disposition of oral imatinib in mice.
    Gardner ER; Smith NF; Figg WD; Sparreboom A
    J Exp Clin Cancer Res; 2009 Jul; 28(1):99. PubMed ID: 19591692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier.
    Bauer M; Römermann K; Karch R; Wulkersdorfer B; Stanek J; Philippe C; Maier-Salamon A; Haslacher H; Jungbauer C; Wadsak W; Jäger W; Löscher W; Hacker M; Zeitlinger M; Langer O
    Clin Pharmacol Ther; 2016 Aug; 100(2):131-41. PubMed ID: 26940368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
    Minocha M; Khurana V; Qin B; Pal D; Mitra AK
    Int J Pharm; 2012 Oct; 436(1-2):127-34. PubMed ID: 22688250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.